{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:53:52Z","timestamp":1789988032829,"version":"4.0.1"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurosci. Bull."],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s12264-025-01354-y","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T12:56:45Z","timestamp":1738760205000},"page":"821-836","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Triple-Target Inhibition of Cholinesterase, Amyloid Aggregation, and GSK3\u03b2 to Ameliorate Cognitive Deficits and Neuropathology in the Triple-Transgenic Mouse Model of Alzheimer\u2019s Disease"],"prefix":"10.1007","volume":"41","author":[{"given":"Junqiu","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4909-2260","authenticated-orcid":false,"given":"Hongfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1099-0509","authenticated-orcid":false,"given":"Zheng","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5507-8524","authenticated-orcid":false,"given":"Kin Yip","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"key":"1354_CR1","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","volume":"397","author":"P Scheltens","year":"2021","unstructured":"Scheltens P, De Strooper B, Kivipelto M, Holstege H, Ch\u00e9telat G, Teunissen CE. Alzheimer\u2019s disease. Lancet 2021, 397: 1577\u20131590.","journal-title":"Lancet"},{"key":"1354_CR2","unstructured":"Collaborators G2D. Global, regional, and national burden of Alzheimer\u2019s disease and other dementias, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019, 18: 88\u2013106."},{"key":"1354_CR3","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1002\/alz.13016","volume":"19","author":"Alzheimer's Association","year":"2023","unstructured":"Association Alzheimer\u2019s. 2023 Alzheimer\u2019s disease facts and figures. Alzheimers Dement 2023, 19: 1598\u20131695.","journal-title":"Alzheimers Dement"},{"key":"1354_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.120861","volume":"306","author":"S Asher","year":"2022","unstructured":"Asher S, Priefer R. Alzheimer\u2019s disease failed clinical trials. Life Sci 2022, 306: 120861.","journal-title":"Life Sci"},{"key":"1354_CR5","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(15)01124-1","volume":"388","author":"P Scheltens","year":"2016","unstructured":"Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, et al. Alzheimer\u2019s disease. Lancet 2016, 388: 505\u2013517.","journal-title":"Lancet"},{"key":"1354_CR6","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/s41422-019-0216-x","volume":"29","author":"X Wang","year":"2019","unstructured":"Wang X, Sun G, Feng T, Zhang J, Huang X, Wang T, et al. Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer\u2019s disease progression. Cell Res 2019, 29: 787\u2013803.","journal-title":"Cell Res"},{"key":"1354_CR7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41582-020-00454-9","volume":"17","author":"H Fillit","year":"2021","unstructured":"Fillit H, Green A. Aducanumab and the FDA\u2014Where are we now? Nat Rev Neurol 2021, 17: 129\u2013130.","journal-title":"Nat Rev Neurol"},{"key":"1354_CR8","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 2023, 330: 512\u2013527.","journal-title":"JAMA"},{"key":"1354_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med 2023, 388: 9\u201321.","journal-title":"N Engl J Med"},{"key":"1354_CR10","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s12264-022-01002-9","volume":"39","author":"W Zhang","year":"2023","unstructured":"Zhang W, Xu J, Dong J, Huang Z, Cao L. Acidification deficiency of autolysosomes induces neuronal autophagic amyloid-\u03b2 plaques in Alzheimer\u2019s disease. Neurosci Bull 2023, 39: 873\u2013876.","journal-title":"Neurosci Bull"},{"key":"1354_CR11","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1093\/brain\/awy132","volume":"141","author":"H Hampel","year":"2018","unstructured":"Hampel H, Mesulam MM, Claudio Cuello A, Farlow MR, Giacobini E, Grossberg GT, et al. The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease. Brain 2018, 141: 1917\u20131933.","journal-title":"Brain"},{"key":"1354_CR12","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.cell.2015.12.056","volume":"164","author":"B De Strooper","year":"2016","unstructured":"De Strooper B, Karran E. The cellular phase of Alzheimer\u2019s disease. Cell 2016, 164: 603\u2013615.","journal-title":"Cell"},{"key":"1354_CR13","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.tig.2018.02.007","volume":"34","author":"J Verheijen","year":"2018","unstructured":"Verheijen J, Sleegers K. Understanding Alzheimer disease at the interface between genetics and transcriptomics. Trends Genet 2018, 34: 434\u2013447.","journal-title":"Trends Genet"},{"key":"1354_CR14","doi-asserted-by":"publisher","first-page":"543","DOI":"10.4103\/1673-5374.320970","volume":"17","author":"Y Ju","year":"2022","unstructured":"Ju Y, Tam KY. Pathological mechanisms and therapeutic strategies for Alzheimer\u2019s disease. Neural Regen Res 2022, 17: 543\u2013549.","journal-title":"Neural Regen Res"},{"key":"1354_CR15","doi-asserted-by":"publisher","first-page":"5157","DOI":"10.1523\/JNEUROSCI.1820-20.2021","volume":"41","author":"C Galanis","year":"2021","unstructured":"Galanis C, Fellenz M, Becker D, Bold C, Lichtenthaler SF, M\u00fcller UC, et al. Amyloid-beta mediates homeostatic synaptic plasticity. J Neurosci 2021, 41: 5157\u20135172.","journal-title":"J Neurosci"},{"key":"1354_CR16","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s40265-015-0529-0","volume":"76","author":"L Bakota","year":"2016","unstructured":"Bakota L, Brandt R. Tau biology and tau-directed therapies for Alzheimer\u2019s disease. Drugs 2016, 76: 301\u2013313.","journal-title":"Drugs"},{"key":"1354_CR17","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1111\/j.1471-4159.2007.05194.x","volume":"104","author":"C Hooper","year":"2008","unstructured":"Hooper C, Killick R, Lovestone S. The GSK3 hypothesis of Alzheimer\u2019s disease. J Neurochem 2008, 104: 1433\u20131439.","journal-title":"J Neurochem"},{"key":"1354_CR18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1365-2990.2006.00795.x","volume":"33","author":"K Leroy","year":"2007","unstructured":"Leroy K, Yilmaz Z, Brion JP. Increased level of active GSK-3beta in Alzheimer\u2019s disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. Neuropathol Appl Neurobiol 2007, 33: 43\u201355.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"1354_CR19","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.molmed.2009.01.003","volume":"15","author":"DP Hanger","year":"2009","unstructured":"Hanger DP, Anderton BH, Noble W. Tau phosphorylation: The therapeutic challenge for neurodegenerative disease. Trends Mol Med 2009, 15: 112\u2013119.","journal-title":"Trends Mol Med"},{"key":"1354_CR20","doi-asserted-by":"publisher","first-page":"15823","DOI":"10.1074\/jbc.M610708200","volume":"282","author":"K Uemura","year":"2007","unstructured":"Uemura K, Kuzuya A, Shimozono Y, Aoyagi N, Ando K, Shimohama S, et al. GSK3beta activity modifies the localization and function of presenilin 1. J Biol Chem 2007, 282: 15823\u201315832.","journal-title":"J Biol Chem"},{"key":"1354_CR21","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1172\/JCI64516","volume":"123","author":"PTT Ly","year":"2013","unstructured":"Ly PTT, Wu Y, Zou H, Wang R, Zhou W, Kinoshita A, et al. Inhibition of GSK3\u03b2-mediated BACE1 expression reduces Alzheimer-associated phenotypes. J Clin Invest 2013, 123: 224\u2013235.","journal-title":"J Clin Invest"},{"key":"1354_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2020.118664","volume":"1867","author":"E Lauretti","year":"2020","unstructured":"Lauretti E, Dincer O, Pratic\u00f2 D. Glycogen synthase kinase-3 signaling in Alzheimer\u2019s disease. Biochim Biophys Acta Mol Cell Res 2020, 1867: 118664.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"1354_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2022.101709","volume":"81","author":"I Terao","year":"2022","unstructured":"Terao I, Honyashiki M, Inoue T. Comparative efficacy of lithium and aducanumab for cognitive decline in patients with mild cognitive impairment or Alzheimer\u2019s disease: A systematic review and network meta-analysis. Ageing Res Rev 2022, 81: 101709.","journal-title":"Ageing Res Rev"},{"key":"1354_CR24","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1111\/jnc.15189","volume":"157","author":"M\u00c1 Cort\u00e9s-G\u00f3mez","year":"2021","unstructured":"Cort\u00e9s-G\u00f3mez M\u00c1, Llorens-\u00c1lvarez E, Alom J, Del Ser T, Avila J, S\u00e1ez-Valero J, et al. Tau phosphorylation by glycogen synthase kinase 3\u03b2 modulates enzyme acetylcholinesterase expression. J Neurochem 2021, 157: 2091\u20132105.","journal-title":"J Neurochem"},{"key":"1354_CR25","first-page":"1161","volume":"117","author":"JP Jia","year":"2004","unstructured":"Jia JP, Jia JM, Zhou WD, Xu M, Chu CB, Yan X, et al. Differential acetylcholine and choline concentrations in the cerebrospinal fluid of patients with Alzheimer\u2019s disease and vascular dementia. Chin Med J (Engl) 2004, 117: 1161\u20131164.","journal-title":"Chin Med J (Engl)"},{"key":"1354_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.108352","volume":"190","author":"G Marucci","year":"2021","unstructured":"Marucci G, Buccioni M, Ben DD, Lambertucci C, Volpini R, Amenta F. Efficacy of acetylcholinesterase inhibitors in Alzheimer\u2019s disease. Neuropharmacology 2021, 190: 108352.","journal-title":"Neuropharmacology"},{"key":"1354_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.103914","volume":"29","author":"J He","year":"2024","unstructured":"He J, Tam KY. Dual-target inhibitors of cholinesterase and GSK-3\u03b2 to modulate Alzheimer\u2019s disease. Drug Discov Today 2024, 29: 103914.","journal-title":"Drug Discov Today"},{"key":"1354_CR28","doi-asserted-by":"crossref","unstructured":"Albertini C, Salerno A, de Sena Murteira Pinheiro P, Bolognesi ML. From combinations to multitarget-directed ligands: A continuum in Alzheimer\u2019s disease polypharmacology. Med Res Rev 2021, 41: 2606\u20132633.","DOI":"10.1002\/med.21699"},{"key":"1354_CR29","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.ejmech.2016.10.060","volume":"128","author":"B Sameem","year":"2017","unstructured":"Sameem B, Saeedi M, Mahdavi M, Shafiee A. A review on tacrine-based scaffolds as multi-target drugs (MTDLs) for Alzheimer\u2019s disease. Eur J Med Chem 2017, 128: 332\u2013345.","journal-title":"Eur J Med Chem"},{"key":"1354_CR30","volume":"2012","author":"T Kramer","year":"2012","unstructured":"Kramer T, Schmidt B, Monte FL. Small-molecule inhibitors of GSK-3: Structural insights and their application to Alzheimer\u2019s disease models. Int J Alzheimers Dis 2012, 2012: 381029.","journal-title":"Int J Alzheimers Dis"},{"key":"1354_CR31","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/0006-2952(61)90145-9","volume":"7","author":"GL Ellman","year":"1961","unstructured":"Ellman GL, Courtney KD, Andres V, Feather-Stone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961, 7: 88\u201395.","journal-title":"Biochem Pharmacol"},{"key":"1354_CR32","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/pro.5560020312","volume":"2","author":"H LeVine 3rd","year":"1993","unstructured":"LeVine H 3rd. Thioflavine T interaction with synthetic Alzheimer\u2019s disease beta-amyloid peptides: Detection of amyloid aggregation in solution. Protein Sci 1993, 2: 404\u2013410.","journal-title":"Protein Sci"},{"key":"1354_CR33","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1021\/acschemneuro.0c00464","volume":"11","author":"Y Ju","year":"2020","unstructured":"Ju Y, Chakravarty H, Tam KY. An isoquinolinium dual inhibitor of cholinesterases and amyloid \u03b2 aggregation mitigates neuropathological changes in a triple-transgenic mouse model of Alzheimer\u2019s disease. ACS Chem Neurosci 2020, 11: 3346\u20133357.","journal-title":"ACS Chem Neurosci"},{"key":"1354_CR34","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/ddr.21631","volume":"81","author":"H Chakravarty","year":"2020","unstructured":"Chakravarty H, Ju Y, Chen WH, Tam KY. Dual targeting of cholinesterase and amyloid beta with pyridinium\/isoquinolium derivatives. Drug Dev Res 2020, 81: 242\u2013255.","journal-title":"Drug Dev Res"},{"key":"1354_CR35","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1089\/adt.2006.029","volume":"5","author":"A Baki","year":"2007","unstructured":"Baki A, Bielik A, Moln\u00e1r L, Szendrei G, Keser\u00fc GM. A high throughput luminescent assay for glycogen synthase kinase-3beta inhibitors. Assay Drug Dev Technol 2007, 5: 75\u201383.","journal-title":"Assay Drug Dev Technol"},{"key":"1354_CR36","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S0896-6273(03)00434-3","volume":"39","author":"S Oddo","year":"2003","unstructured":"Oddo S, Caccamo A, Shepherd JD, Paul Murphy M, Golde TE, Kayed R, et al. Triple-transgenic model of Alzheimer\u2019s disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron 2003, 39: 409\u2013421.","journal-title":"Neuron"},{"key":"1354_CR37","doi-asserted-by":"publisher","first-page":"497","DOI":"10.4155\/bio-2015-0014","volume":"8","author":"W Zhou","year":"2016","unstructured":"Zhou W, Wu X, Li J, Hu X, Tam KY. Quantification of permanent positively charged compounds in plasma using one-step dilution to reduce matrix effect in MS. Bioanalysis 2016, 8: 497\u2013509.","journal-title":"Bioanalysis"},{"key":"1354_CR38","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.neuropharm.2018.01.003","volume":"131","author":"X Wu","year":"2018","unstructured":"Wu X, Kosaraju J, Zhou W, Tam KY. SLOH, a carbazole-based fluorophore, mitigates neuropathology and behavioral impairment in the triple-transgenic mouse model of Alzheimer\u2019s disease. Neuropharmacology 2018, 131: 351\u2013363.","journal-title":"Neuropharmacology"},{"key":"1354_CR39","doi-asserted-by":"publisher","first-page":"580","DOI":"10.3390\/biom11040580","volume":"11","author":"D De Boer","year":"2021","unstructured":"De Boer D, Nguyen N, Mao J, Moore J, Sorin EJ. A comprehensive review of cholinesterase modeling and simulation. Biomolecules 2021, 11: 580.","journal-title":"Biomolecules"},{"key":"1354_CR40","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/0304-3940(94)90064-7","volume":"177","author":"H Tohgi","year":"1994","unstructured":"Tohgi H, Abe T, Hashiguchi K, Saheki M, Takahashi S. Remarkable reduction in acetylcholine concentration in the cerebrospinal fluid from patients with Alzheimer type dementia. Neurosci Lett 1994, 177: 139\u2013142.","journal-title":"Neurosci Lett"},{"key":"1354_CR41","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3389\/fneur.2020.00614","volume":"11","author":"S Manzano","year":"2020","unstructured":"Manzano S, Ag\u00fcera L, Aguilar M, Olazar\u00e1n J. A review on tramiprosate (homotaurine) in Alzheimer\u2019s disease and other neurocognitive disorders. Front Neurol 2020, 11: 614.","journal-title":"Front Neurol"},{"key":"1354_CR42","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1515\/revneuro-2014-0076","volume":"26","author":"A Zare-Shahabadi","year":"2015","unstructured":"Zare-Shahabadi A, Masliah E, Johnson GVW, Rezaei N. Autophagy in Alzheimer\u2019s disease. Rev Neurosci 2015, 26: 385\u2013395.","journal-title":"Rev Neurosci"},{"key":"1354_CR43","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1126\/science.1204592","volume":"332","author":"C Settembre","year":"2011","unstructured":"Settembre C, Di Malta C, Polito VA, Garcia Arencibia M, Vetrini F, Erdin S, et al. TFEB links autophagy to lysosomal biogenesis. Science 2011, 332: 1429\u20131433.","journal-title":"Science"},{"key":"1354_CR44","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.3390\/ijms23031709","volume":"23","author":"HY Pan","year":"2022","unstructured":"Pan HY, Valapala M. Regulation of autophagy by the glycogen synthase kinase-3 (GSK-3) signaling pathway. Int J Mol Sci 2022, 23: 1709.","journal-title":"Int J Mol Sci"},{"key":"1354_CR45","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.tins.2016.02.002","volume":"39","author":"H Martini-Stoica","year":"2016","unstructured":"Martini-Stoica H, Xu Y, Ballabio A, Zheng H. The autophagy-lysosomal pathway in neurodegeneration: A TFEB perspective. Trends Neurosci 2016, 39: 221\u2013234.","journal-title":"Trends Neurosci"},{"key":"1354_CR46","doi-asserted-by":"publisher","first-page":"8094","DOI":"10.1002\/jcp.27588","volume":"234","author":"MS Uddin","year":"2019","unstructured":"Uddin MS, Mamun AA, Labu ZK, Hidalgo-Lanussa O, Barreto GE, Ashraf GM. Autophagic dysfunction in Alzheimer\u2019s disease: Cellular and molecular mechanistic approaches to halt Alzheimer\u2019s pathogenesis. J Cell Physiol 2019, 234: 8094\u20138112.","journal-title":"J Cell Physiol"},{"key":"1354_CR47","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40478-016-0292-9","volume":"4","author":"A Piras","year":"2016","unstructured":"Piras A, Collin L, Gr\u00fcninger F, Graff C, R\u00f6nnb\u00e4ck A. Autophagic and lysosomal defects in human tauopathies: Analysis of post-mortem brain from patients with familial Alzheimer disease, corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathol Commun 2016, 4: 22.","journal-title":"Acta Neuropathol Commun"},{"key":"1354_CR48","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1016\/j.bmcl.2013.02.017","volume":"23","author":"A Romero","year":"2013","unstructured":"Romero A, Cacabelos R, Oset-Gasque MJ, Samadi A, Marco-Contelles J. Novel tacrine-related drugs as potential candidates for the treatment of Alzheimer\u2019s disease. Bioorg Med Chem Lett 2013, 23: 1916\u20131922.","journal-title":"Bioorg Med Chem Lett"},{"key":"1354_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1476-5381.2010.00661.x","volume":"160","author":"S Phukan","year":"2010","unstructured":"Phukan S, Babu VS, Kannoji A, Hariharan R, Balaji VN. GSK3beta: Role in therapeutic landscape and development of modulators. Br J Pharmacol 2010, 160: 1\u201319.","journal-title":"Br J Pharmacol"},{"key":"1354_CR50","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.biopsych.2019.05.008","volume":"87","author":"A Di Meco","year":"2020","unstructured":"Di Meco A, Curtis ME, Lauretti E, Pratic\u00f2 D. Autophagy dysfunction in Alzheimer\u2019s disease: Mechanistic insights and new therapeutic opportunities. Biol Psychiatry 2020, 87: 797\u2013807.","journal-title":"Biol Psychiatry"},{"key":"1354_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2021.101464","volume":"72","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Yang X, Song YQ, Tu J. Autophagy in Alzheimer\u2019s disease pathogenesis: Therapeutic potential and future perspectives. Ageing Res Rev 2021, 72: 101464.","journal-title":"Ageing Res Rev"},{"key":"1354_CR52","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1083\/jcb.200505082","volume":"171","author":"WH Yu","year":"2005","unstructured":"Yu WH, Cuervo AM, Kumar A, Peterhoff CM, Schmidt SD, Lee JH, et al. Macroautophagy\u2014a novel Beta-amyloid peptide-generating pathway activated in Alzheimer\u2019s disease. J Cell Biol 2005, 171: 87\u201398.","journal-title":"J Cell Biol"},{"key":"1354_CR53","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s41593-022-01084-8","volume":"25","author":"JH Lee","year":"2022","unstructured":"Lee JH, Yang DS, Goulbourne CN, Im E, Stavrides P, Pensalfini A, et al. Faulty autolysosome acidification in Alzheimer\u2019s disease mouse models induces autophagic build-up of A\u03b2 in neurons, yielding senile plaques. Nat Neurosci 2022, 25: 688\u2013701.","journal-title":"Nat Neurosci"},{"key":"1354_CR54","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1080\/15548627.2020.1728095","volume":"17","author":"I Benito-Cuesta","year":"2021","unstructured":"Benito-Cuesta I, Ord\u00f3\u00f1ez-Guti\u00e9rrez L, Wandosell F. AMPK activation does not enhance autophagy in neurons in contrast to MTORC1 inhibition: Different impact on \u03b2-amyloid clearance. Autophagy 2021, 17: 656\u2013671.","journal-title":"Autophagy"},{"key":"1354_CR55","doi-asserted-by":"publisher","DOI":"10.15252\/embj.201798804","volume":"37","author":"R Puertollano","year":"2018","unstructured":"Puertollano R, Ferguson SM, Brugarolas J, Ballabio A. The complex relationship between TFEB transcription factor phosphorylation and subcellular localization. EMBO J 2018, 37: e98804.","journal-title":"EMBO J"},{"key":"1354_CR56","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1038\/s41467-018-04849-7","volume":"9","author":"L Li","year":"2018","unstructured":"Li L, Friedrichsen HJ, Andrews S, Picaud S, Volpon L, Ngeow K, et al. A TFEB nuclear export signal integrates amino acid supply and glucose availability. Nat Commun 2018, 9: 2685.","journal-title":"Nat Commun"},{"key":"1354_CR57","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1038\/s41418-022-01028-6","volume":"29","author":"A Tan","year":"2022","unstructured":"Tan A, Prasad R, Lee C, Jho EH. Past, present, and future perspectives of transcription factor EB (TFEB): Mechanisms of regulation and association with disease. Cell Death Differ 2022, 29: 1433\u20131449.","journal-title":"Cell Death Differ"},{"key":"1354_CR58","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.1038\/s41418-021-00822-y","volume":"28","author":"D Sakellariou","year":"2021","unstructured":"Sakellariou D, Tiberti M, Kleiber TH, Blazquez L, L\u00f3pez AR, Abildgaard MH, et al. eIF4A3 regulates the TFEB-mediated transcriptional response via GSK3B to control autophagy. Cell Death Differ 2021, 28: 3344\u20133356.","journal-title":"Cell Death Differ"},{"key":"1354_CR59","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/ncb3407","volume":"18","author":"Y Li","year":"2016","unstructured":"Li Y, Xu M, Ding X, Yan C, Song Z, Chen L, et al. Protein kinase C controls lysosome biogenesis independently of mTORC1. Nat Cell Biol 2016, 18: 1065\u20131077.","journal-title":"Nat Cell Biol"},{"key":"1354_CR60","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41392-023-01608-z","volume":"8","author":"V Panwar","year":"2023","unstructured":"Panwar V, Singh A, Bhatt M, Tonk RK, Azizov S, Raza AS, et al. Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease. Signal Transduct Target Ther 2023, 8: 375.","journal-title":"Signal Transduct Target Ther"},{"key":"1354_CR61","doi-asserted-by":"publisher","first-page":"911","DOI":"10.3233\/JAD-140426","volume":"41","author":"ML Campanari","year":"2014","unstructured":"Campanari ML, Garc\u00eda-Ayll\u00f3n MS, Belbin O, Galcer\u00e1n J, Lle\u00f3 A, S\u00e1ez-Valero J. Acetylcholinesterase modulates presenilin-1 levels and \u03b3-secretase activity. J Alzheimers Dis 2014, 41: 911\u2013924.","journal-title":"J Alzheimers Dis"},{"key":"1354_CR62","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.3390\/ijms24021437","volume":"24","author":"M\u00c1 Cort\u00e9s-G\u00f3mez","year":"2023","unstructured":"Cort\u00e9s-G\u00f3mez M\u00c1, Barber\u00e1 VM, Alom J, S\u00e1ez-Valero J, Garc\u00eda-Ayll\u00f3n MS. Presenilin 1 modulates acetylcholinesterase trafficking and maturation. Int J Mol Sci 2023, 24: 1437.","journal-title":"Int J Mol Sci"},{"key":"1354_CR63","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.cbi.2012.08.010","volume":"203","author":"P Jing","year":"2013","unstructured":"Jing P, Zhang JY, Ouyang Q, Wu J, Zhang XJ. Lithium treatment induces proteasomal degradation of over-expressed acetylcholinesterase (AChE-S) and inhibit GSK3\u03b2. Chem Biol Interact 2013, 203: 309\u2013313.","journal-title":"Chem Biol Interact"},{"key":"1354_CR64","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.7150\/ijbs.57078","volume":"17","author":"H Zhang","year":"2021","unstructured":"Zhang H, Wei W, Zhao M, Ma L, Jiang X, Pei H, et al. Interaction between a\u03b2 and tau in the pathogenesis of Alzheimer\u2019s disease. Int J Biol Sci 2021, 17: 2181\u20132192.","journal-title":"Int J Biol Sci"},{"key":"1354_CR65","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13069","volume":"19","author":"JX Song","year":"2020","unstructured":"Song JX, Malampati S, Zeng Y, Durairajan SSK, Yang CB, Tong BC, et al. A small molecule transcription factor EB activator ameliorates beta-amyloid precursor protein and Tau pathology in Alzheimer\u2019s disease models. Aging Cell 2020, 19: e13069.","journal-title":"Aging Cell"},{"key":"1354_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108122","volume":"235","author":"Y Cho","year":"2022","unstructured":"Cho Y, Bae HG, Okun E, Arumugam TV, Jo DG. Physiology and pharmacology of amyloid precursor protein. Pharmacol Ther 2022, 235: 108122.","journal-title":"Pharmacol Ther"},{"key":"1354_CR67","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.4103\/1673-5374.257511","volume":"14","author":"R Coronel","year":"2019","unstructured":"Coronel R, Palmer C, Bernabeu-Zornoza A, Monteagudo M, Rosca A, Zambrano A, et al. Physiological effects of amyloid precursor protein and its derivatives on neural stem cell biology and signaling pathways involved. Neural Regen Res 2019, 14: 1661\u20131671.","journal-title":"Neural Regen Res"},{"key":"1354_CR68","doi-asserted-by":"publisher","first-page":"9359","DOI":"10.1074\/jbc.M707108200","volume":"283","author":"MH Magdesian","year":"2008","unstructured":"Magdesian MH, Carvalho MMVF, Mendes FA, Saraiva LM, Juliano MA, Juliano L, et al. Amyloid-beta binds to the extracellular cysteine-rich domain of Frizzled and inhibits Wnt\/beta-catenin signaling. J Biol Chem 2008, 283: 9359\u20139368.","journal-title":"J Biol Chem"}],"container-title":["Neuroscience Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12264-025-01354-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12264-025-01354-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12264-025-01354-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T13:04:37Z","timestamp":1745327077000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12264-025-01354-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,5]]},"references-count":68,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1354"],"URL":"https:\/\/doi.org\/10.1007\/s12264-025-01354-y","relation":{},"ISSN":["1673-7067","1995-8218"],"issn-type":[{"value":"1673-7067","type":"print"},{"value":"1995-8218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,5]]},"assertion":[{"value":"15 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest and have nothing to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}